Clinical Trial Update: Japanese Bridging Study Conducted in the United States [Phase 1]

View source ↗

Summary

Bristol-Myers Squibb’s Phase 1 bridging trial for a Hepatitis C virus therapy conducted in the United States has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hepatitis C Virus | Phase 1 | Status: WITHDRAWN